首页> 外文期刊>Blood: The Journal of the American Society of Hematology >CD141+ dendritic cells produce prominent amounts of IFN-α after dsRNA recognition and can be targeted via DEC-205 in humanized mice.
【24h】

CD141+ dendritic cells produce prominent amounts of IFN-α after dsRNA recognition and can be targeted via DEC-205 in humanized mice.

机译:dsRNA识别后,CD141 +树突状细胞会产生大量的IFN-α,并且可以通过DEC-205靶向人源化小鼠。

获取原文
获取原文并翻译 | 示例
           

摘要

Functional differences between human dendritic cell (DC) subsets and the potential benefits of targeting them with vaccines remain poorly defined. Here we describe that mice with reconstituted human immune system components (huNSG mice) develop all human conventional and plasmacytoid DC compartments in lymphoid organs. Testing different Toll-like receptor agonists for DC maturation in vivo, we found that IL-12p70 and interferon (IFN)-α production correlated with the maturation of CD141+ (BDCA3+) conventional DCs in huNSG mice. Furthermore, depletion of CD141+ DCs before stimulation significantly reduced IFN-α levels in vivo. This DC subset produced similar total amounts but different subtypes of IFN-α in response to synthetic double-stranded RNA compared with plasmacytoid DCs in response to a single-stranded RNA equivalent. Moreover, synthetic double-stranded RNA as adjuvant and antigen targeting to the endocytic receptor DEC-205, a combination that focuses antigen presentation for T-cell priming on CD141+ DCs, stimulated antigen-specific human CD4+ T-cell responses. Thus, the human CD141+ DC subset is a prominent source of IFN-α and interleukin-12 production and should be further evaluated for vaccine development.
机译:人类树突状细胞(DC)子集之间的功能差异以及用疫苗靶向它们的潜在好处仍然知之甚少。在这里,我们描述了具有重组人类免疫系统成分的小鼠(huNSG小鼠)在淋巴器官中发育了所有人类常规细胞和浆细胞样DC区室。测试不同的Toll样受体激动剂体内DC成熟,我们发现IL-12p70和干扰素(IFN)-α的产生与huNSG小鼠中CD141 +(BDCA3 +)常规DC的成熟相关。此外,刺激前耗尽CD141 + DCs会显着降低体内的IFN-α水平。与对单链RNA等同物的浆细胞样DC相比,该DC亚类对合成的双链RNA的应答产生了相似的总量,但是具有不同的亚型。此外,合成的双链RNA作为佐剂和靶向内吞受体DEC-205的抗原(刺激抗原呈递用于T细胞引发CD141 + DC的组合)刺激了抗原特异性人CD4 + T细胞应答。因此,人CD141 + DC亚群是IFN-α和白介素12产生的主要来源,应进一步评估疫苗的开发。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号